NDAINJECTIONINJECTABLE
Approved
Sep 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
CALCIJEX (calcitriol) by AbbVie is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). First approved in 1986.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CALCIJEX (calcitriol) is the active form of vitamin D3, administered by injection to regulate calcium and phosphorus metabolism. It works by binding to calcitriol receptors in the intestine and bone to stimulate calcium absorption and correct hypocalcemia in patients with renal failure. The drug addresses secondary hyperparathyroidism and renal osteodystrophy, conditions caused by the kidney's inability to synthesize calcitriol endogenously.
LOE Approaching
Product approaching loss of exclusivity with modest competitive pressure (30%), suggesting potential team rightsizing and transition planning in the coming 2–3 years.
Mechanism of Action
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on CALCIJEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.